Key Segmentation:
By Treatment Type
-
Subcutaneous Immunotherapy (SCIT)
-
Sublingual Immunotherapy (SLIT)
By Type
-
Tablets
-
Drops
By Allergy Type
-
Allergic Rhinitis
-
Allergic Asthma
-
Food Allergy
-
Others
By Distribution Channel
-
Hospital Pharmacy
-
Retail Pharmacy
-
Online Pharmacy
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g. Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
Frequently Asked Questions
Ans: The Allergy Immunotherapy Market is expected to grow at a CAGR of 9.5% from 2026 to 2035.
Ans: The Allergy Immunotherapy Market was valued at USD 2.1 billion in 2025.
Ans: Favorable regulatory approvals and an expanding product pipeline - encompassing SLIT tablet approvals, food allergy OIT and biologic therapies, and landmark approvals such as the FDA's clearance of omalizumab for multi-food allergy protection - are the primary structural growth drivers, alongside the escalating global burden of allergic diseases affecting an estimated 30–40% of the world's population.
Ans: Subcutaneous Immunotherapy (SCIT) dominated the Allergy Immunotherapy Market in 2025 with approximately 65% of global revenue, owing to its decades of clinical validation as the gold standard for severe allergic disease management, strong physician adoption, and established insurance reimbursement infrastructure across North America and Europe.
Ans: North America dominated the Allergy Immunotherapy Market in 2025, accounting for approximately 38% of global market revenue, driven by the high prevalence of allergic diseases in the U.S., advanced FDA regulatory frameworks for both SCIT and SLIT products, strong allergist clinical network infrastructure, and robust insurance reimbursement policies for immunotherapy treatment protocols.
Get in Touch
